Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $124.3 million.

  • Relay Therapeutics' Cash & Equivalents fell 39.90% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year decrease of 39.90%. This contributed to the annual value of $124.3 million for FY2024, which is 13.53% down from last year.
  • Latest data reveals that Relay Therapeutics reported Cash & Equivalents of $124.3 million as of FY2024, which was down 13.53% from $143.7 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' Cash & Equivalents ranged from a high of $447.6 million in FY2020 and a low of $124.3 million during FY2024.
  • In the last 3 years, Relay Therapeutics' Cash & Equivalents had a median value of $143.7 million in 2023 and averaged $139.9 million.
  • Data for Relay Therapeutics' Cash & Equivalents shows a maximum YoY tumbled of 45.81% (in 2022) over the last 5 years.
  • Relay Therapeutics' Cash & Equivalents (Yearly) stood at $447.6 million in 2020, then tumbled by 37.42% to $280.1 million in 2021, then tumbled by 45.81% to $151.8 million in 2022, then dropped by 5.31% to $143.7 million in 2023, then dropped by 13.53% to $124.3 million in 2024.